| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.15 | 0.004 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.14 | 0.004 |